Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 43.6% in February

Vigil Neuroscience, Inc. (NASDAQ:VIGL) was the recipient of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 1,020,000 shares, a drop of 43.6% from the January 31st total of 1,810,000 shares. Based on an average trading volume of 1,060,000 shares, the days-to-cover ratio is currently 1.0 days. Currently, 5.2% of the shares of the stock are sold short.

Institutional Trading of Vigil Neuroscience

Several hedge funds and other institutional investors have recently bought and sold shares of VIGL. Woodline Partners LP boosted its stake in Vigil Neuroscience by 239.1% in the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company’s stock worth $831,000 after buying an additional 344,614 shares in the last quarter. Blair William & Co. IL purchased a new stake in Vigil Neuroscience in the fourth quarter worth approximately $551,000. Renaissance Technologies LLC boosted its stake in Vigil Neuroscience by 698.5% in the fourth quarter. Renaissance Technologies LLC now owns 367,300 shares of the company’s stock worth $624,000 after buying an additional 321,300 shares in the last quarter. abrdn plc boosted its stake in shares of Vigil Neuroscience by 124.9% during the fourth quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after purchasing an additional 293,461 shares during the period. Finally, Trustees of Columbia University in the City of New York purchased a new stake in shares of Vigil Neuroscience during the fourth quarter valued at approximately $328,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on VIGL. Guggenheim reiterated a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. HC Wainwright reiterated a “buy” rating and set a $17.00 price target on shares of Vigil Neuroscience in a research report on Thursday, January 23rd. William Blair began coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They set an “outperform” rating for the company. Wedbush lifted their price target on Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Finally, JMP Securities reiterated a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $19.75.

Vigil Neuroscience Stock Performance

VIGL traded down $0.05 during midday trading on Friday, hitting $2.42. The stock had a trading volume of 119,349 shares, compared to its average volume of 1,519,188. The company has a market cap of $98.93 million, a P/E ratio of -1.17 and a beta of 1.84. The business has a fifty day moving average of $2.22 and a 200 day moving average of $2.87. Vigil Neuroscience has a 1 year low of $1.49 and a 1 year high of $6.06.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.